… plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 …
… Topotecan is currently the only drug approved in Europe in a second-line setting for the
treatment of small-cell lung cancer. … superior to topotecan as a second-line treatment in patients …
treatment of small-cell lung cancer. … superior to topotecan as a second-line treatment in patients …
An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
S Patel, WJ Petty, JM Sands - Therapeutic Advances in …, 2021 - journals.sagepub.com
… was active in this population given that chemotherapy plus … Lurbinectedin compares favorably
to other drugs on the list of … phase III study of lurbinectedin/doxorubicin versus topotecan …
to other drugs on the list of … phase III study of lurbinectedin/doxorubicin versus topotecan …
[HTML][HTML] Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment
L Lambrecht, P Arnold, J Behr, P Mertsch, A Tufman… - Diagnostics, 2024 - ncbi.nlm.nih.gov
… Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase
… Organization for Research and Treatment of Cancer Early Clinical Studies Group and New …
… Organization for Research and Treatment of Cancer Early Clinical Studies Group and New …
[PDF][PDF] Comparative assessment of three different second-line regimens in chemotherapy resistant/refractory small-cell lung cancer
I Hacibekiroglu, O Ozkul, E Cakir, O Kostek… - Journal of BU ON …, 2021 - jbuon.com
… targeted therapy and immunotherapy have also been actively tested … After relapse, topotecan
is the only second-line drug … phase II study of weekly topotecan as second-line therapy for …
is the only second-line drug … phase II study of weekly topotecan as second-line therapy for …
Extensive-stage small-cell lung cancer: first-line and second-line treatment options
J Zugazagoitia, L Paz-Ares - Journal of Clinical Oncology, 2022 - ascopubs.org
… Until June 2020, oral or intravenous topotecan was the only drug … two randomized phase
III trials, where topotecan showed extended … Lurbinectedin is also being actively evaluated in …
III trials, where topotecan showed extended … Lurbinectedin is also being actively evaluated in …
[HTML][HTML] Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study
Y Du, XY Liu, XY Si, XT Zhang, JY Zhou… - … Lung Cancer …, 2024 - ncbi.nlm.nih.gov
… Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase
… Organization for Research and Treatment of Cancer Early Clinical Studies Group and New …
… Organization for Research and Treatment of Cancer Early Clinical Studies Group and New …
[HTML][HTML] Lurbinectedin in small cell lung cancer
A Manzo, V Sforza, G Carillio, G Palumbo… - Frontiers in …, 2022 - frontiersin.org
… by the Food and Drug Administration as second line for SCLC … , was the only second-line
treatment approved for SCLC … of topotecan was evaluated in a randomized phase III clinical …
treatment approved for SCLC … of topotecan was evaluated in a randomized phase III clinical …
[HTML][HTML] Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel
F Meriggi - Cancers, 2024 - mdpi.com
… ones, have shown that A is active and relatively well-tolerated in … A phase III randomized trial
comparing A with topotecan in … alkylating drug Lurbinectedin (L) was evaluated in a phase II …
comparing A with topotecan in … alkylating drug Lurbinectedin (L) was evaluated in a phase II …
[HTML][HTML] Novel cytotoxic chemotherapies in small cell lung carcinoma
D Cortinovis, P Bidoli, S Canova, F Colonese… - Cancers, 2021 - mdpi.com
… , few novel chemotherapy drugs have been developed in the latest … As a second-line treatment,
a phase III randomised trial … , second-line belotecan has been compared to topotecan in a …
a phase III randomised trial … , second-line belotecan has been compared to topotecan in a …
[HTML][HTML] … doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials …
V Ernani, R Jahan, LM Smith, AS Marr… - Cancer treatment and …, 2020 - Elsevier
… rovalpituzumab tesirine versus topotecan in the second-line setting was … topotecan followed
by weekly doxorubicin is a safe and active regimen in patients with relapsed small cell lung …
by weekly doxorubicin is a safe and active regimen in patients with relapsed small cell lung …